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ABSTRACT
Uracil-DNA glycosylase (UDG) compromises the
replication strategies of diverse viruses from unre-
lated lineages. Virally encoded proteins therefore
exist to limit, inhibit or target UDG activity for pro-
teolysis. Viral proteins targeting UDG, such as the
bacteriophage proteins ugi, and p56, and the HIV-1
protein Vpr, share no sequence similarity, and are
not structurally homologous. Such diversity has
hindered identification of known or expected UDG-
inhibitory activities in other genomes. The structural
basis for UDG inhibition by ugi is well characterized;
yet, paradoxically, the structure of the unbound p56
protein is enigmatically unrevealing of its mechan-
ism. To resolve this conundrum, we determined
the structure of a p56 dimer bound to UDG. A helix
from one of the subunits of p56 occupies the UDG
DNA-binding cleft, whereas the dimer interface
forms a hydrophobic box to trap a mechanistically
important UDG residue. Surprisingly, these p56
inhibitory elements are unexpectedly analogous
to features used by ugi despite profound archi-
tectural disparity. Contacts from B-DNA to UDG
are mimicked by residues of the p56 helix, echoing
the role of ugi’s inhibitory beta strand. Using
mutagenesis, we propose that DNA mimicry by
p56 is a targeting and specificity mechanism
supporting tight inhibition via hydrophobic
sequestration.
INTRODUCTION
Interactions between cells and viruses prime the develop-
ment and acquisition of a multitude of cellular innate
immune responses and, reciprocally, anti-restriction
strategies. The archetypal examples are restriction-
modiﬁcation systems of prokaryotes as defences against
bacteriophages. DNA bacteriophages are found to select
against host restriction endonuclease recognition sequences
in their genomes (1). DNA phages also use genome-
cloaking methods, such as base modiﬁcation (2–4) or the
incorporation of non-canonical DNA nucleotides such as
deoxyuridine (5,6), to evade restriction enzyme recognition
or cleavage. Although uracilation of DNA may afford pro-
tection to viral genomes from restriction endonucleases
(3,4), it is nevertheless a prime substrate for the ubiquitous
cellular DNA base-excision repair (BER) pathway. Uracil-
DNA therefore paradoxically appears to provide no
defence against catastrophic disintegration of viral
genomes (7). There nonetheless exist viruses, which
subvert host nucleotide biosynthesis so that thymidine is
replaced entirely by deoxyuridine in the viral genomic
DNA, such as the Bacillus phage PBS1 (and its clear-
plaque isotype PBS2), which survives by encoding an
early protein ‘ugi’ that neutralizes the ﬁrst step of BER
by stoichiometric enzyme inhibition (2,5,8–11).
The BER pathway may be considered as a two part
process: in the ﬁrst part, the target base is removed, and
the site is primed for repair by creation of a break in the
DNA backbone; then, in the second part, DNA repair is
enacted. BER is primed to act on a relatively small but
signiﬁcant number of aberrant bases within a genome that
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may arise at any time, predominantly from ambient
cellular processes. Deoxyuridine is such a target for
BER, as it may naturally arise by spontaneous deamin-
ation of deoxycytidine, which would lead to C:G to T:A
transition mutations. However, active incorporation of
deoxyuridine during the replication of certain viruses
will result in an unusually high concentration of uracil.
Under these conditions, uracil-DNA BER promotes
DNA double-strand breaks due to the proximity of sub-
strate sites on the paired DNA strands. A viral DNA
genome in which all thymidine is supplanted by
deoxyuridine would therefore be reduced to a non-viable
pool of fragments by the action of BER (7,8).
In eubacteria and most eukaryotes, the archetypal
uracil-DNA glycosylase (UDG) is primarily active in
uracil-DNA BER. UDG represents family 1 of a super-
family of enzymes with sequence and structural homology
in their functional motifs (12–14). UDG is exquisitely
selective for uracil bases located in single- or double-
stranded DNA, and it selectively removes uracil by
cleaving the N-glycosyl linkage between the base and the
deoxyribose, leaving behind an abasic site (15). UDG is
able to non-speciﬁcally bind and scan DNA bases,
capturing thymine and uracil due to natural DNA
breathing motions that cause them to un-pair and par-
tially emerge from the helical centre of DNA. By a
squeezing and pinching deformation of B-DNA structure
and concomitant insertion of a loop into the minor
groove, UDG is able to exaggerate this breathing
motion of DNA. UDG facilitates this by providing a
pseudo base pair for a purine base via the residue at the
apex of its minor groove intercalation loop. This intercal-
ation also results in the pyrimidine base of the erstwhile
pair being ﬂipped out of the helix entirely and prolongs its
residency in the UDG concave active site. Thymidine is
observed to meet a steric block and would then regress
into the DNA helical core. Deoxycytidine is also
rejected, whereas deoxyuridine can progress into the cata-
lytic centre of UDG and is efﬁciently liberated as uracil
(16,17) (Supplementary Figure S1). Family 1 UDG is the
BER initiating enzyme that is targeted by a stoichiometric
active site inhibitor: the ugi protein encoded by uracil-
DNA phage PBS1 to preserve the integrity of its uracil-
DNA genome (10,11).
Branches 2–7 of the UDG superfamily are characterized
by their close structural and functional homology or
analogy and may be identiﬁed and grouped by their oc-
currence in the domains of life and the particular patterns
of motif conservation or variation (12–14). Metazoan
genomes may encode more than one type of uracil-DNA
BER activity, of which some may be active at different
times of the cell cycle or in different tissue types or
cellular processes (18). Superfamily alternatives to UDG
in eubacteria are ancillary and generally less active uracil-
DNA BER activators, which can however deal with
bulkier base adducts (19). The UDG superfamily is also
represented in extremophiles, as well as in some viruses of
disparate lineages (12–14,20,21). In studies of other
branches of the UDG superfamily, there are indications
that ugi is at least partially inhibitory towards uracil-DNA
repair activities other than family 1 UDG, when
mixed in vitro with cell lysates of relevant organisms
(20). It has also been reported that certain branches of
the UDG superfamily appear to be unaffected by ugi,
the PBS1 phage inhibitor that targets family 1 UDG.
However, considering the striking conservation of DNA-
binding site structure, this is most likely attributable to
residue variations in conserved motifs (19,21) (Figure 1).
Interestingly, some of the phages reported to encode
UDG-inhibitory activities do not replace thymine with
uracil in their genomic DNA and are instead thought to
inhibit UDG to avoid the random occurrence of nicks due
to BER in their replicating genomes (22). Salient phages in
this category are coliphage T5, and the family of Bacillus
phages that includes f29, Nf, PZA, B-103 and GA-1. The
identity of the UDG inhibitory activity detected on infec-
tion by T5 is yet to be conﬁrmed. It is not obvious when
considering the reported biophysical properties of the in-
hibitor, which of several candidate open reading frames
(ORFs) in the ﬁrst 8% of the T5 genome will encode this
activity (23). There is no encoded sequence within this
region of the T5 genome with obvious sequence similarity
either to ugi, or to the protein inhibitors of UDG encoded
by the family of Bacillus phages that include f29. Indeed,
these p56 proteins and the related protein from phage GA-
1 show no sequence homology to ugi, and furthermore a
reported structure of the free p56 inhibitor displayed no
structural homology to ugi (22,24).
The natural target of ugi is Bacillus subtilis UDG;
however, structural analyses have used various homo-
logues from Human Herpesvirus 1 (HHV-1), Homo
sapiens and Escherichia coli, in which all the characteristic
structural features involved in irreversible inhibition are
conserved (Figure 1). Meanwhile, mycobacterial UDG
homologues are observed to interact with ugi reversibly,
largely owing to residue differences in key motifs (25).
UDG and ugi form a tight 1:1 stoichiometric complex
with an expansive and predominantly polar interface.
The UDG DNA-binding cleft is occupied by ugi via
stereochemical mimicry of contacts that would otherwise
be productively formed by distorted B-DNA (10,11,26).
Blockade of the UDG DNA-binding cleft is achieved by
an ugi beta strand and is supported by sequestration of the
pre-catalytic pseudo base pairing hydrophobic residue at
the apex of the UDG DNA minor groove intercalation
loop. This arrangement provides exquisite speciﬁcity of
ugi to UDG, rather than to DNA-binding proteins per
se: signiﬁcant variations in this minor groove intercalating
loop, such as in vaccinia virus UDG, are sufﬁcient to
confound ugi inhibition (11,21).
Some observations indicate similarities between UDG
contacts made by ugi and p56 proteins, respectively. For
example, p56 and a relative encoded by phage GA-1, both
make essential contacts with the hydrophobic residue on
the apex of the UDG minor groove DNA intercalation
loop and can be displaced from UDG by ugi implying a
similar site of binding (27,28). The p56 protein in its apo-
form, however, does not resemble ugi (a monomeric
inhibitor of UDG) and, among other differences,
features a hydrophobic alpha helical dimer interface,
demonstrated by mutagenesis to be indispensible for
UDG inhibition (24). Therefore, owing to the radically
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different architecture of p56 when compared with ugi, in-
spection of the apo-p56 structure alone cannot lead to a
prediction of its mechanism of inhibition of UDG, despite
data in support of commonality of interactions.
In the present study, we have sought to address the
enigmatic question of the structural basis of ostensibly
similar UDG inhibition by entirely unrelated viral
proteins. To this end, we have determined the structure
of a UDG—p56 complex, and despite the architectural
disparity between these two types of inhibitor, we can
now observe why the inhibition of UDG, whether
imparted by ugi or by p56, is functionally analogous.
We ﬁnd that both types of inhibitor form corresponding
interactions with UDG that are surprisingly mutually
superimposable and map faithfully to contacts observed
in X-ray structures of double-stranded DNA bound to
UDG (16). Furthermore, both inhibitor types, in architec-
turally dissimilar ways, target the UDG DNA minor
groove intercalation loop: a key mechanistic component
in UDG substrate recognition and catalysis. Using a com-
bination of mutagenesis, equilibration of pre-formed
UDG—p56 complexes with free ugi protein, and
analysing the effects of free p56 on other members of
the UDG superfamily, we propose that p56 DNA
mimicry engenders initial targeting and selectivity of
UDG: a prelude to tight binding reminiscent of the most
avid macromolecular interactions.
We also analyse the convergence on exquisitely
selective functional analogy by entirely unrelated
UDG inhibitors and discuss its implications for the
existence and discovery of other BER modulating
proteins at large.
MATERIALS AND METHODS
TOPO (Invitrogen) plasmids were selected and maintained
with 50 mg/ml kanamycin. All other plasmids were selected
and maintained with 100 mg/ml ampicillin. LB media were
according to Miller. Enzymes and buffers for PCR, DNA
modiﬁcation and cloning were supplied by New England
Biolabs (NEB) and used according to manufacturer’s rec-
ommendations. Synthetic oligonucleotides were supplied
by Euroﬁns-MWG-Operon. Unless otherwise speciﬁed,
general reagents were supplied by Sigma-Aldrich. Details
of oligonucleotides, genetic sequences and schematic dia-
grams are in the Supplementary File.
Cloning of PZA p56 and HHV-1 UDG for bi-cistronic
recombinant expression
The protein sequence accession for Bacillus phage PZA
p56 (GenBank: AAA88480.1) was reverse translated
in silico with E. coli optimized codon usage (29). The syn-
thetic gene (Supplementary File) was supplied in a
standard TA-cloning vector by Euroﬁns-MWG-Operon.
HHV-1 UDG was obtained from the construct pTS106.1
(15).
A bi-cistronic cassette was designed (Supplementary
File) with p56 as the ﬁrst ORF, separated from UDG
(the second ORF) by a natural intergenic sequence
Figure 1. HHV-1, human and E. coli UDG are among the most completely characterized UDGs, including structural data of their association with
the PBS1 encoded stoichiometric inhibitor, ugi. Bacillus subtilis UDG is the natural target of the inhibitors ugi and p56. Sequence identity between
these UDGs is highlighted in cyan. Positions marked with a gold triangle show important points of contact between HHV-1 UDG and p56 observed
in this study, which are also seen in contacts between distorted B-DNA with human UDG-DNA in structure 1SSP (Figure 3, and Supplementary
Table S1). MUG (E. coli), TDG (human) and SMUG (Xenopus) are other enzymes from the wider UDG superfamily, but important residues in ugi
and p56 inhibition are not conserved, these are indicated by aligning only these residues; those residues that are conserved between these enzymes and
family 1 UDGs shown, are indicated by a circle above. The orange highlighted region is the UDG minor groove intercalation loop apical hydro-
phobic residue (phenylalanine in B. subtilis, leucine in other UDGs shown) sequestered by ugi and p56. The presence of an arginine at this position in
SMUG and TDG suggests lack of susceptibility to ugi or p56 (see main text). Residue substitutions across the much more highly conserved family 1
UDGs can affect attributes such as turnover and dissociation kinetics, and therefore might also modulate interactions with inhibitor proteins.
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followed by an artiﬁcial tag-encoding sequence. The
chosen intergenic sequence naturally separates the E. coli
genes mopA and mopB (which encode GroEL and
GroES). The artiﬁcial tag-encoding sequence comprised
nucleotides encoding a 10His tag, followed by a Strep
Tag II, and ﬁnally a TEV protease recognition motif.
HHV-1 UDG was ampliﬁed with a 50-end encoding
from: ‘GGVSP . . . ’. Synthetic PZA p56, HHV-1 UDG
and the mop intergenic sequence were ampliﬁed by PCR
using Phusion DNA polymerase, with primers that
deﬁned restriction sites convenient for cloning. The
tag-encoding sequence was formed from overlapping
oligonucleotides, phosphorylated with T4 polynucleotide
kinase and ligated at elevated temperature using Taq
DNA ligase. The individual amplicons and intact tag
sequence were then gel puriﬁed from 1.6% agarose,
using a QIAquick gel extraction kit (QIAGEN) subse-
quent to electrophoresis.
The cassette was formed by catenation via overlap
extension PCR, which used 2 ng of each of the four
puriﬁed DNA molecules, with outer primers for p56
(coding strand homology, primer P1), and HHV-1 UDG
(reverse strand homology, primer U2). The p56 ORF thus
formed the 50 end of the cassette, followed by the mop
intergenic region, then by the synthetic tags and ﬁnally,
HHV-1 UDG formed the 30 end. The 50 extremity of the
chimera comprised a restriction site for NdeI; the 30
extremity comprised a HindIII restriction site.
The cassette amplicon was captured into a pCR-Blunt-
II-TOPO vector (Invitrogen) and propagated in NEB5a
cells (NEB). DNA sequencing (GATC Biotech) indicated
100% sequence identity to that predicted.
A pRSET-C plasmid (Invitrogen) was digested using
NdeI and HindIII restriction enzymes, in the presence of
CIP alkaline phosphatase and gel puriﬁed from 0.8%
agarose. The bi-cistronic cassette was released from the
latterly described TOPO clone by digestion with NdeI
and HindIII restriction enzymes and gel puriﬁed from
1% agarose. The plasmid and cassette were ligated using
NEB Quick Ligase and propagated in NEB5a cells before
ﬁnal a DNA sequencing check. The plasmid was
designated pRSC2056.
Site-directed mutagenesis and associated construct
modiﬁcation
Oligonucleotides were designed to perform PCR of the
pRSC2056 plasmid (Supplementary File). Mutations to
p56 created construct modiﬁcations E37Q, E37D, Y40N,
E37D/Y40N, respectively (designated pRSC2056mn,
where n could be Q for E37Q, E for E37D, Y for Y40N
or d for E37D/Y40N). Mutations were deﬁned at least
11 nt from the 30-end on one of a pair of primers; the
second primer extended the template in the opposing dir-
ection, and there was no overlap and no gap between the
50-end priming sites of the two primers.
The primers were phosphorylated with T4 polynucleo-
tide kinase before their use in an 18 cycle PCR performed
using Phusion DNA polymerase. After PCR, 10 units of
DpnI restriction enzyme were added directly to the 50 ml of
PCR reactions, and tubes were incubated for 90min at
37C. Reaction volumes were then expanded to 100 ml
with 1 T4 DNA ligase buffer (NEB) including 400
units of T4 DNA ligase. The tubes were further incubated
for 2 h at 30C, before propagation in NEB5a cells. DNA
sequencing was used to identify mutants, indicating muta-
genesis efﬁciencies of 25–100%.
In addition, for the bi-cistronic expression plasmids
pRSC2056 and the three p56 mutants E37D, Y40N and
E37D/Y40N, a variant construct was also created by
deletion of the bulk of the HHV-1 UDG ORF. These
plasmids would therefore express only p56 protein (wild-
type, or a given mutant, respectively) on induction. The
UDG deletion plasmids were designated pRSCU56n,
where n was any of: W for wild-type, E for E37D, Y for
Y40N or d for E37D/Y40N. These constructs were
created by separately digesting each plasmid using NheI
and XhoI restriction enzymes. The incompatible over-
hangs were then ﬁlled in by incubating 75 ng of each
plasmid in 20 ml of reactions with 1 Thermopol buffer
(NEB), supplemented with 0.3mM dNTPs and 4 units
VentR
 DNA polymerase, incubating at 72C for
15min. The reactions were each then expanded to 50 ml
with 1 T4 DNA ligase buffer incorporating 400 units
T4 DNA ligase and incubated at 30C for 2 h, before
propagation in NEB5a cells. Colony PCR with Taq
DNA polymerase indicated success rates of >80% per
six colonies screened per construct modiﬁcation reaction.
DNA sequencing conﬁrmed the anticipated adjustments.
Expression and puriﬁcation of a PZA p56 – HHV-1
UDG complex
High yield recombinant expression of the p56 – UDG
complex from the pRSC2056 plasmid was performed in
T7 Express lysY cells at 37C in liquid LB including 2%
(w/v) a-D-glucose. Scrapings from 8% (v/v) glycerol
stocks at 80C were used to inoculate 5ml of pre-
cultures (one per destination 2 l ﬂask) in liquid LB
including 2% (w/v) a-D-glucose, shaken at 37C for 16 h.
Subsequent to harvest at 5000g, cell pellets were resus-
pended in fresh broth as a homogeneous mixture, to
seed the expression cultures.
Large-scale growth for expression was performed in 2 l
capacity (bafﬂed/ﬂuted) Erlenmeyer ﬂasks, containing
500ml of liquid LB including 2% (w/v) a-D-glucose.
These were inoculated at 1/100 (v/v) from the pre-
culture resuspensions then incubated at 37C with
shaking at 220 rpm until the culture reached an absorb-
ance at 600 nm of 0.8–1.0. At this point, each culture was
induced by the addition of IPTG to 0.2mM, followed by
16 h further growth at 37C.
Cells were harvested by centrifugation at 5000g, and
pellets were resuspended on ice into 30ml of ice-cold
resuspension buffer per 5 g wet weight of cells. The resus-
pension buffer was 100mM Tris–HCl, 200mM Arginine,
150mM NaCl, 10% glycerol, 1mM EDTA, 1mM PMSF,
with a ﬁnal pH of 7.8. Pellets were immediately frozen at
20C.
Pellets were partially thawed at 37C, placed in wet ice
and sonicated with three rounds of 6 s pulses over 5min
periods, at 60W using a Sonics Vibra-cell ultrasonic
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processor. The lysate was treated with ice-cold strepto-
mycin sulphate [ﬁnal concentration 1% (w/v)], along
with 100 mg egg-white avidin, and then incubated on ice
for 30min. The treated lysate was subsequently
centrifuged at 45 000g for 50min in a Beckman Coulter
Avanti J-20 XP centrifuge with JA25.50 rotor. The super-
natant fraction was then 0.2 mm ﬁltered and applied to a
5ml StrepTactin superﬂow cartridge (GE-Healthcare),
equilibrated with the same buffer used to resuspend
the harvested cells except that PMSF was omitted.
Subsequent to sample loading, the cartridge was washed
with 10 column volumes of the PMSF-free buffer. Elution
used the PMSF-free buffer, supplemented with 2.5mM
desthiobiotin. The peak eluate (typically 30ml) was
placed in a 14–16K cut-off dialysis bag and 0.2mg TEV
protease [prepared from an in-house construct, according
to criteria reported elsewhere (30)] was added to the
contents. The bag was dialysed with stirring for 12 h at
4C against 2 l of 20mM Tris–HCl, 200mM NaCl at pH
7.8. The dialysed sample was concentrated at 3200g to a
ﬁnal volume of 10ml in a Vivaspin-20 concentrator
(Sartorius) with a 10 000MW cut-off and loaded onto a
Superdex 75 HiLoad 26/60 prep grade gel-ﬁltration
column (GE-Healthcare). Two distinct peaks were
eluted: analysis by Coomassie stained SDS–PAGE
revealed that peak one comprised two species consistent
with the expected migration characteristics of PZA p56
and HHV-1 UDG, implying their association, whereas
peak two was identiﬁed by comparative assay as TEV
protease and not UDG. Peak one fractions, an apparent
complex of PZA p56 and HHV-1 UDG, were
concentrated as previously described until the concentra-
tion was between 2 and 4mg/ml then stored at 4C.
Protein thus stored was suitable for crystallization for
periods of months under these conditions.
Expression and puriﬁcation of PZA p56 mutants
co-expressed with HHV-1 UDG
Expression and puriﬁcation of each of the four p56
mutants was performed exactly as stated in the previous
section, concerning the wild-type p56 complex with HHV-
1 UDG. The mutant E37Q exhibited puriﬁcation charac-
teristics indistinguishable from wild-type p56 co-expressed
with HHV-1 UDG. However, for the other three mutants,
SDS–PAGE analysis revealed that only UDG was present
in eluted fractions from StrepTactin, whereas the p56
mutants (E37D, Y40N or E37D/Y40N) were assessed to
be in the column ﬂow-through fraction (Supplementary
File).
Expression and puriﬁcation of apo PZA p56 and apo p56
mutant derivatives
High yield recombinant expression of p56 apo proteins
from the pRSCU56n plasmids was performed in T7
Express lysY cells as described for the pRSC2056
plasmid, with some modiﬁcations. Large-scale growth
for expression was performed in 0.5 l capacity
Erlenmeyer ﬂasks, containing 100ml capacity liquid LB
including 2% (w/v) a-D-glucose. These were inoculated
at the equivalent of 1/100 from the pre-culture
resuspensions and then incubated at 37C with shaking
at 200 rpm until the culture reached an absorbance at
600 nm of 0.5–0.8. At this point, each culture was
induced by the addition of IPTG to 0.2mM, followed
by 16 h further growth at 30C.
Cells were harvested as described for pRSC2056;
however, the resuspension buffer was 20mM
Na-HEPES, 300mM NaCl with a ﬁnal pH of 7.5.
Pellets were immediately frozen at 20C. Pellets were
lysed as described for pRSC2056; however, incubation
with streptomycin sulphate and egg-white avidin was
omitted. The ﬁltered supernatant fraction was obtained
as described for pRSC2056 and then diluted 6-fold in
20mM Na-HEPES buffer (pH 7.5) such that NaCl was
adjusted to 50mM, before loading onto a 5ml
Q-sepharose FastFlow cartridge (GE-Healthcare),
equilibrated with 20mM Na-HEPES, 50mM NaCl (pH
7.5). Subsequent to sample loading, the cartridge was
washed with 10–20 column volumes of equilibration
buffer until the asymptote closely approached the
baseline. Elution was achieved via an isocratic NaCl
gradient over 20 column volumes to an end point of
1.6M NaCl. The peak eluates were obtained at
150mM NaCl and concentrated at 3200g to a ﬁnal
volume of 250 ml in a Vivaspin-20 concentrator
(Sartorius) with a 3000MW cut-off and loaded onto a
Superdex 75 Tricorn 10/300GL gel-ﬁltration column
(GE-Healthcare), pre-equilibrated in the cell resuspension
buffer. Peak fractions were re-concentrated, and a second
round of gel ﬁltration was performed to obtain essentially
homogeneous protein as assessed by Coomassie-stained
SDS–PAGE. Proteins were stored at concentrations of
1mg/ml at 4C. Proteins were also observed to remain
in solution at 4C in the tens of mg/ml range.
Gel shifts and activity/inhibition assays
For gel-shift experiments and activity/inhibition assays, all
proteins were adjusted by dialysis or SEC, to 20mM Na-
HEPES, 150mM NaCl (pH 7.8). In addition to the p56 –
UDG complex and the wild-type and mutant apo p56
proteins, the following were also prepared: HHV-1
UDG apo protein (15), E. coli MUG protein (19) and
PBS1 ugi protein (31). Finally, E. coli UDG and
HsSMUG were obtained from NEB.
All gel shifts were performed by adjusting target protein
concentrations such that peak heights of >50 to
<200mAU were observed on passage through a
Superdex 75 Tricorn 10/300GL gel-ﬁltration column on
an A¨kta FPLC system (GE-Healthcare). The column
ﬂow rate was set at 1ml per minute for all runs, and the
protein volume entering the column was 200 ml on each
run. Protein mixtures were pre-mixed and held on ice for
4 h before column entry. Fraction sizes were set at 0.5ml
and 12 or 13.5% SDS–PAGE stained with Instant Blue
(Expedeon), was used to analyse 20 ml each of peak frac-
tions. In the case of p56 mutants Y40N and E37D/Y40N,
owing to lower yield and therefore more dilute fractions,
up to 100 ml was vacuum evaporated to 20 ml before
SDS–PAGE analysis. For vacuum concentrated samples,
gels were run slowly until the dye front crossed the stacking
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zone into the resolving gel. This was done to minimize
effects arising from the concentrated buffer and salt in
such samples; however, banding anomalies and artefacts
are nonetheless possible under such conditions.
To monitor enzyme activity and its inhibition, a DNA
substrate was prepared by PCR with Taq DNA polymer-
ase, using a dNTP mix in which deoxyuridine entirely
supplanted thymidine. Reactions were performed at
37C for 30min in total volumes of 24 ml [1 NEB
buffer #3 for HHV-1 UDG, 1 NEB buffer #1 for
HsSMUG, 1 UDG assay buffer (NEB) for E. coli
UDG] incorporating 5 units of Endonuclease IV (Nfo)
(NEB), which was also the case for control DNA
samples. Preliminary titration of substrate and enzymes
was performed to scout for a level of turnover that
could be tracked by agarose gel electrophoresis in the
format of a visual ‘wysiwyg’ assay. Agarose gels were
1% (w/v) and contained SYBR Safe - DNA Gel Stain
(Invitrogen). Gels were run with tanks packed in ice with
ice-cold 1 TAE buffer, and images were captured with a
BioDoc ItTM imaging system and Benchtop UV
Transilluminator (UVP). HHV-1 UDG was deployed at
3.6 pmol per reaction (150 nM); apo p56 inhibitor was
deployed equimolar with UDG, whereas titration of
mutants spanned a wide molar excess over UDG from
2-fold to 345-fold. UDG assays were performed with
HHV-1 UDG and quality controlled against a commer-
cially obtained E. coli UDG (NEB). Owing to a lack of
information concerning its molarity, HsSMUG (NEB)
assays deployed p56 wild-type at 3.2 mM (77.5 pmol,
1 mg), whereas p56 mutants were deployed at a nominal
excess of 53.5mM (1.285 nmol, 16.5 mg). Controls for the
visual assay included reactions without Nfo to check for
signs of non-speciﬁc nuclease activity and microgram
quantities of BSA to control for any effects arising from
the more excessive relative molar ratios of p56 inhibitor
proteins.
Crystallographic analysis of a PZA p56 – HHV-1
UDG complex
Aliquots of the PZA p56 – HHV-1 UDG complex were
transferred to a 10 kDa cut-off Amicon concentrator and
spun at 6000g until the ﬁnal concentration was 5.3mg/ml.
At this concentration, the complex was prone to precipi-
tation and had to be used immediately. Crystallization
plates for initial screening were prepared using the
Mosquito micro volume crystallization robot at both 2:1
and 1:1 ratios of protein to precipitant with volumes of
0.1 ml:0.5 ml and 0.075 ml:0.075 ml. Optimization blocks
were prepared using the Multiprobe II liquid handling
robot producing 96-well grids varying precipitant concen-
trations using the four-corner approach to aid robotic
setup (32).
From multiple hits in the initial screens, all producing
crystals with a similar morphology, two conditions [28 and
90 of the Molecular Dimensions JCSG screen (33)] yielded
promising crystals and were further optimized. Condition
28 contained 10% w/v PEG 6K with 0.1M HEPES (pH
7), and condition 90 contained 0.1M Ammonium Acetate
17% PEG 10K with 0.1M Bis-Tris (pH 5.5). Crystals
grown in an optimized variant of JCSG condition 90
[0.09M Ammonium Acetate, 14.3% PEG 10K, 0.1M
Bis-Tris (pH 5.5)] displayed the highest quality diffraction.
Crystals exhibited a ﬂat rectangular plate morphology
with maximum observed dimensions for the largest face
around 50 mm by 20 mm. Crystallographic parameters are
given in Table 1.
Crystals were ﬂash frozen in liquid nitrogen immedi-
ately following their transfer from crystallization
droplets into a cryprotectant solution, consisting of the
precipitant and 30% ethylene glycol. Cryo X-ray data
were collected on beamline IO4-1 at the DIAMOND
light source facility. Data sets were collected with a ﬁne
slicing methodology using the PILATUS detector (34) and
oscillation of 0.15, exposure of 0.15 s and a transmission
of 75% for 1200 images. Initial beam-line processing was
performed using the XIA2 pipeline (35,36). Further pro-
cessing used the programs XDS (37) and AIMLESS (38).
Early data set processing revealed a signiﬁcant anisotropy
in the C* direction. Although still present in the ﬁnal data,
anisotropy was acceptably low with the half data set cor-
relation in the C* direction dropping below 0.5 at 2.46 A˚.
The structure was successfully phased by molecular re-
placement with the program PHASER (35,38) using 1
UDG [the apo form of HHV-1 UDG (15)] and 2LE2
[the apo form of f29 p56 (24)], respectively, as search
models, searching for two and four copies, respectively.
The two copies of UDG located were designated mol-
ecules A and B, whereas the four located copies of the
p56 monomer were designated molecules C through F.
The resulting map contained no clashes and was structur-
ally consistent with a biologically signiﬁcant complex.
Further rounds of reﬁnement used the BUSTER suite
of reﬁnement tools (39), and building used the program
Table 1. Crystallographic data collection and reﬁnement statistics
Data collection
Space group P212121
Cell dimensions
a, b, c (A˚) 52.70, 91.38 162.86
a, b, g () 90.0, 90.0, 90.0
Resolution (A˚) 81.43-2.13 (2.22-2.13)
Rsym or Rmerge 0.067 (0.572)
I / sI 14.3 (2.3)
Completeness (%) 99.2 (99.2)
Redundancy 4.6 (4.6)
Reﬁnement
Resolution (A˚) 2.13
No. reﬂections 44499
Rwork / Rfree 0.171/0.202
No. atoms
Protein 5212
Ligand/ion 52
Water 409
B-factors
Protein 44.39
Ligand/ion 55.73
Water 46.29
R.M.S. deviations
Bond lengths (A˚) 0.01
Bond angles () 1.01
Ramachandran evaluation Favoured 98.75% Outliers 0.0%
Molprobity score 1.06 100th Percentile
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COOT (35,40). Reﬁnement of the structure yielded high-
quality maps for the majority of observed molecules, with
the exception of molecule B. Residues 17–60 of molecule B
are located adjacent to a large solvent channel in the
crystal and poorly ordered in the structure. Omission of
the region resulted in clear positive density in fo-fc differ-
ence maps but the 2fo-fc maps with the region replaced
were consistently poor, especially for side chains.
Reﬁnement improved with NCS dropped from this
region and TLS reﬁnement introduced with separate op-
erators for the region as well as for each separate chain.
Some side chains were still not visible, and these were
cropped back to Cb atoms. The ﬁnal reﬁnement statistics
are shown in Table 1, the overall structure is shown in
Figure 2, and the structure is deposited in the PDB with
the accession number 4L5N.
Volume calculations were carried out using the analysis
program VOIDOO (41) using a probe sphere of 1.4 A˚.
RESULTS
PZA p56 and HHV-1 UDG form a stable 2:1
stoichiometric complex
Protein p56 of bacteriophage PZA, when co-expressed
with HHV-1 UDG in E. coli, appeared to form a stable
complex. Afﬁnity tag puriﬁcation of HHV-1 UDG
resulted in co-puriﬁcation of just one other protein, con-
sistent in molecular mass with PZA p56. Dialysis of this
material overnight with TEV protease resulted in the
expected adjustment in molecular mass of HHV-1 UDG
following tag removal, to within 1 kD of the mass of TEV
protease (as evidenced using Coomassie SDS–PAGE).
Subsequent gel ﬁltration was nevertheless able to resolve
HHV-1 UDG from TEV protease, even though the mass
difference between these two proteins is <1 kD. This was
only possible because HHV-1 UDG co-migrates in a peak
some 14 kD larger than anticipated for its apo-form. SDS–
PAGE analysis revealed this effect to be due to co-migra-
tion with a protein migrating at circa 7 kD. This implies
that a dimer of a 7 kD protein, consistent with our
knowledge of p56, co-migrates with HHV-1 UDG. It is
therefore surmised that PZA p56 and HHV-1 UDG
remain productively associated from expression through
concentration for crystallization.
Overall structure of the PZA p56:HHV-1 UDG complex
As previously reported, UDG forms a single domain struc-
ture consisting of an initial left-handed coil of helices
followed by a bab structure that forms an internal
four-stranded parallel b-sheet with external a-helices (15).
Figure 2. HHV-1 UDG (molecule A, in main text; shown here in light blue) in complex with PZA p56 [PDB accession 4L5N]. The subunits of p56 are
coloured to support the descriptions in the text: molecule C (shown here in yellow and brown) makes the most extensive interactions via its docked helix
(the brown segment), which includes forming two sides of a hydrophobic pit that traps UDG leucine 214 (see main text for details), whereas molecule D, as
well as forming the remaining two sides of the hydrophobic pit, makes just one other notable interaction with UDG (see main text).
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The active site cleft occurs at the end of the sheet where
strands 2 and 3 part, with important residues occurring on
loops emanating from each of the strands as described pre-
viously (15,16). The p56 monomer comprises a three-
stranded antiparallel b-sheet with a helix lying along it.
The biological dimer is observed to form a six-membered
sheet with the helices lying against one another forming a
single hydrophobic core (24) (Figure 2).
Most interactions between PZA p56 and HHV-1 UDG
in complex (PDB entry 4L5N) are made via the helix of
one of the subunits of the inhibitor dimer (molecule C or
molecule E, but C only will be referred to henceforth for
ease of clarity) (Figure 3a). This p56 helix ﬁts into the
UDG DNA-binding cleft (molecule A or molecule B,
but only referred to as A henceforth), effectively
mimicking DNA (Figures 2b and 3). Supporting this, a
small hydrophobic pocket, formed of mirror residues
within the helices of the dimer, traps the apical leucine
of the HHV-1 UDG DNA minor groove intercalation
loop (a phenylalanine in B. subtilis UDG), which would
normally insert into the DNA helix whenever UDG
samples an un-paired base (Figure 5).
p56 occupies the UDG DNA-binding cleft via an
alpha helix
Reminiscent of inhibition by ugi (Figure 3c), the UDG
active site is occupied by p56. However, where ugi
achieves this blockade with a distorted edge-on beta
strand, p56 almost exclusively uses the alpha helix of
one of its monomeric subunits (molecule C). Contacts to
the UDG DNA-binding cleft from this p56 helix span
Ser32 through Asn42. The ﬁnal contact is via Glu26,
which is part of the underlying b-sheets of the inhibitor.
Thr43 of the less-associated subunit of the p56 dimer
(molecule D; NB: equivalent to molecule F) makes one
of only three contacts in total from this subunit
(Supplementary Figure S2).
p56 provides DNA mimetic contacts to UDG analogous to
those of ugi
Many of the HHV-1 UDG interaction points of p56 mir-
ror those made by DNA to UDG, as observed in the
structure of human UDG bound to DNA (PDB entry
1SSP) (Figure 3a and b) (16). Several hydroxyl and
A B C
Figure 3. Comparative orientations of UDG bound to p56, DNA, and ugi, with detailed views of the UDG-binding pocket containing both substrate
and inhibitor elements on a UDG surface. UDG residues are shown with blue carbon atoms as is the surface, whereas substrate and inhibitor residues are
shown with yellow carbon atoms. The second dimer of p56 is shown in green. (A) The p56 inhibitory helix bound to the HHV-1 UDG. Only the
interacting side chains of the inhibitory helix and Glu26 of p56 are shown alongside UDG interacting residues. (B) Backbone of the uracil-containing
strand of DNA bound to human UDG (PDB: 1SSP). (C) Residues of the ugi inhibitory strand bound to human UDG (PDB: 1UGH).
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backbone oxygen interactions closely resemble those
formed by the phosphates of the DNA backbone in the
kinked conformation exhibited when the uracil base is
ﬂipped out (Figure 4). Most residues that stabilize phos-
phates in the DNA-bound structure have an inhibitor
residue interacting with it either directly or via a water
moiety (Supplementary Table S1). In comparison, ugi
forms a similar number of interactions via its DNA
mimicking b-strand (Figure 3c) (10,11). Ugi has an
extended interaction with additional points of contact to
UDG, and several interactions peripheral to the inhibi-
tory strand, relative to p56 (with reference to the HHV-1
UDG complex). The combination of these factors may
contribute to ugi’s reported ability to displace p56 from
UDG (22).
p56 DNA mimicry at position 1 relative to the UDG
catalytic pocket
The phosphate before that of the ﬂipped out base (phos-
phate 1) makes polar contacts with His148 in the 1SSP
structure (Figure 4a); this is mimicked in the p56 bound
structure by interactions with p56 Glu26 a residue from
the underlying sheets rather than the helix occupying the
UDG DNA binding cleft (Figure 4b). HHV-1 UDG
contains two histidine residues in this region, and both
appear in close proximity to the inhibitor residue.
p56 DNA mimicry at the UDG catalytic pocket and at
relative position+1
In the human UDG complex with DNA, the phosphate of
the catalysed base (phosphate 0) makes multiple inter-
actions with the N and Og of Ser169 (in the Serine-
Proline loop that is important in the pinching mechanism
of the enzyme) as well as long-range interactions via a
water molecule to Gln152 (Figure 4c). These interactions
are faithfully repeated in the p56 bound structure with the
UDG serine residue NH interacting with the backbone
oxygen of p56 Gly41, and the UDG serine OH forming
a tight hydrogen bond network via a water with p56
Asn42 Od1 and the backbone oxygen of p56 Val38. The
DNA interaction with a UDG glutamine is also mimicked
through p56 Asn41 O, again via water (Figure 4d). The
phosphate following this interacts with Ser270 (human
UDG) of the intercalation loop as well as Gln144
(Figure 4e). The bond with the corresponding HHV-1
UDG serine is again mimicked in the inhibitor structure
via Glu37 of the inhibitor (Figure 4f).
p56 mimicry at position+2 relative to the UDG catalytic
pocket
The phosphate at position+2 from the catalysed base is the
ﬁnal point of DNA mimicry in the HHV-1 complex with
p56. This interacts with (human UDG) Ser273 on the other
side of the intercalation loop as well as backbone nitrogen
atoms of loops on the other side of the binding cleft (Figure
4g). In the HHV-1 UDG – p56 complex, this is to some
extent the exception to superimposable DNA mimicry, as
interactions from p56 are noticeably different. Although
Ser215 of the UDG DNA minor groove intercalation
loop, and p56 Glu37 Oe1 do interact via water, Thr190
(counterpart to serine 247 human UDG) has no close con-
nection. This paucity of interaction may be partly
compensated by nearby contacts that are not DNA
mimetic, such as the next UDG residue, His191, via a
water molecule from p56 Ser32, whereas the side chain
Ne2 of UDG Gln87 is seen to bond with Asp35. Finally,
Ser34 of the p56 inhibitor could potentially interact but
exhibits the wrong geometry in our structure (Figure 4h).
Analogy in hydrophobic sequestration of a UDG
mechanism-speciﬁc leucine
The tightest point of interaction in the p56 complex
appears to be the minor groove intercalation loop of
UDG (Figure 5). The apical leucine residue ﬁts into a
deep pit between the two helices of the inhibitor dimer.
This box-sided pit is formed by a rigid interaction of
mutually perpendicular pairs of residues from each p56
subunit helix. Glu37 and Tyr40 side chains from p56
molecules C and D, form the walls of the box. Two
opposing corners of the box are formed by hydrogen
bonds between the Tyr40 OZ and the carboxyl Oe2 of
Glu37. The remaining corners of the box are formed by
main chain helical hydrogen bonds between Glu37 and
Gly41. The base of the pit is formed by the rings of 2
phenylalanine residues. Despite the presence of the two
carboxyl groups in the top corners of this trap, the
leucine residue is favourably buried within the hydropho-
bic interior. When buried in this way, the two ﬂanking
serines of the UDG intercalation loop each form
hydrogen bonds from their side chain hydroxyls to
either end of Glu37 (molecule C). One of these
hydrogen bonds is to the side chain carboxyl of Glu37
via a water molecule and the other is to the main chain
oxygen, creating the semblance of a hydrophilic ‘lid’ for
the box that could presumably make any egress of the
leucine unfavourable.
We sought to test the importance of any lid closure via a
p56 E37Q mutant (data not shown), as it is possible that
the intermediary water molecule might not be retained for
the interaction with serine in UDG. However, there still
exists a possibility that this water molecule is present
because when we view the 3 A˚ structure of the E37Q p56
complex with HHV-1 UDG, we do not see any signiﬁcant
main chain or side chain rearrangements in this area
relative to the wild-type complex (within the margins of
error at this resolution), but neither is this a suitable reso-
lution to conﬁdently place a water molecule. Given the
apparent structural parity, one could easily speculate
that the glutamine head group might rotate 180
(relative to the wild-type conﬁguration) to satisfy inter-
actions with the p56 Tyr40 hydroxyl and the water
bridge to UDG serine.
Regardless of the relative importance of the polar lid,
however, there is once again analogy with ugi in p56 se-
questration of this apical leucine residue in a UDG
complex. Using the program Voidoo (41), we calculate
that ugi sequesters HHV-1 UDG leucine in a relatively
broader hydrophobic well of 149.3 A˚3, where there
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Figure 4. Comparison of UDG-DNA backbone phosphate interactions versus UDG with the inhibitory helix of p56. The UDG carbon atoms are
shown in blue, whereas DNA and inhibitor carbon atoms are in yellow. Numbering of UDG residues in left hand side panels (A,C,E,G) refer to
human UDG, whereas numbering in right hand side panels (B,D,F,H) refer to HHV-1 UDG; these are equivalent views of the two enzymes. (A/B)
Area 1 base upstream of the catalysed uracil base compared with the equivalent region with the p56 inhibitor bound. (C/D) Region containing the
phosphate of the catalysed uracil compared with that with p56 bound. (E/F) The phosphate 1 base downstream of the catalysed uracil compared
with that with p56 bound. (G/H) The ﬁnal phosphate with signiﬁcant interactions and the equivalent region with p56 bound.
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appears to be more space particularly near the rim in com-
parison with the narrow slot of only 86.4 A˚3 created by the
hydrophobic box of p56. Leucine 214 (and its equivalents
in other UDGs) adopts different conformations in the
various structures available for analysis. In the apo form
of HHV-1 UDG, Leu214 adopts a conformation similar
to that observed in the described complex with p56, with a
shift of 0.5 A˚ in Ca position but with a similar sidechain
conformation; this conformation is also similar in apo
human UDG. The ugi bound structure of HHV-1 UDG
has a similar Ca position with just 0.4 A˚ difference, but the
opposite leucine conformer is adopted. This conformer is
the same in ugi sequestered human, and E. coli, UDGs
and is therefore likely attributable to a small shift in the
position of the hydrophobic trap in ugi relative to p56. It
is notable that sequestration of the UDG leucine is a
UDG-speciﬁc binding feature supporting DNA mimicry
that is already contoured to the particular distortions
imposed on B-DNA by UDG during binding. This re-
markable convergence on an exquisitely UDG-speciﬁc
mechanism by both p56 and ugi is both unexpected and
surprisingly analogous considering the structural disparity
between the two types of inhibitor and their converse
functional architecture.
Mutations underline the central importance of the p56
hydrophobic trap
The results of gel shift experiments and inhibitor titrations
into enzyme reactions point to the central importance of
the p56 box-shaped hydrophobic trap. We designed the
mutations with a notion that they would distort the
geometry and internal volume of the hydrophobic trap
such that binding of the apical hydrophobic residue of
the UDG minor groove DNA intercalation loop would
be compromised while also aiming to retain the dimeric
structure of p56.
Our results would imply that the p56 mutation E37D
does not disrupt the dimer interface because the apo
protein appears to behave like wild-type p56 in gel ﬁltra-
tion chromatography. We also observe, however, that p56
E37D has a reduced interaction with HHV-1 UDG: this
p56 mutant does not co-migrate in afﬁnity chromatog-
raphy following co-expression with afﬁnity tagged UDG
(see overloaded sample on SDS–PAGE in Supplementary
File), though it does retain an ability to co-migrate with
UDG through gel ﬁltration (when both proteins have been
separately pre-puriﬁed and mixed) (Table 2; also
Supplementary File); yet, it does not block UDG
activity even at a molar ratio of 50:1 but does so
Figure 5. The ‘box-shaped’ hydrophobic pit of the p56 inhibitor dimer with UDG (mol A) leucine 214 inserted. The surface of p56, as well as
important residues, is shown in yellow, whereas the UDG carbon atoms are shown in light blue. UDG (mol A) serines 212, and 215, interact with
both charged and polar elements of p56 (mol C) Glu37 at the upper rim of the pit, creating a ‘lid’ (see main text).
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imperfectly (versus a control of an equimolar complex of
HHV-1 UDG and wild-type 56) at 100:1 (Table 2; also
Supplementary File). Clearly, the indications are that
these proteins associate, but not particularly efﬁciently.
Simulation based on the experimental parameters would
imply that productive complexes are in the region of 10%
(Supplementary Figure S3) (42).
In the case of the Y40N p56 mutation, the situation is
complicated by the fact that the dimer interface also
appears to be compromised. On gel ﬁltration, there is a
distinct two-peak trace, which could represent an
aggregated form of the mutant protein (transit time
similar to the complex between wild-type p56 and
HHV-1 UDG, but no band for UDG visible on over-
loaded SDS-PAGE sample lanes) and what could plaus-
ibly be the monomer (evidenced by indistinguishable
banding relative to that seen in the dimer peak on
SDS–PAGE): relative peak heights would indicate the
monomeric form is predominant. Although co-migration
(at a low proportion) of pre-mixed HHV-1 UDG and p56
(Y40N) in gel ﬁltration cannot be ruled out, it should be
born in mind that other data for this mutant do not
support this. In assay, there is no inhibition of UDG
detectable up to 345-fold molar excess. In keeping with
these observations, Y40N does not co-purify with afﬁnity
tagged HHV-1 UDG from co-expression lysates and its
yield following puriﬁcation is markedly lower than either
wild-type or E37D p56. The double mutant (E37D/
Y40N) displays similar properties to the Y40N single
mutant and is also apparently ineffective in blocking
UDG activity; however, owing to a markedly lower
yield post-puriﬁcation, the upper limit of this mutant
form of p56 for inhibition assays was a 65-fold molar
excess over HHV-1 UDG. This mutant also does not
co-purify in afﬁnity chromatography with co-expressed
afﬁnity tagged HHV-1 UDG. These data would suggest
that the dimer interface is signiﬁcantly compromised in
the Y40N containing mutants.
Taken together, the data from E37D, Y40N and
E37D/Y40N mutations of p56 underline the importance
of p56 targeting a single UDG residue via a hydrophobic
trap. When the mutant data are considered along with
behaviour of p56 in competition with ugi, as detailed in
the next section, this hydrophobic interaction would
appear to be superior in avidity to the supporting
DNA mimetic interactions, which are largely water
mediated.
p56 speciﬁcally targets family 1 UDG
It is distinctly possible that as well as suggestions of
charge-mediated alignment of p56 with UDG (24) as pre-
viously suggested for binding of UDG by ugi (11), the
DNA mimetic helix of p56 might be more important for
speciﬁcity of targeting. This can be tested in part by an-
swering the question of whether p56 can inhibit other
classes of the UDG superfamily, which have highly
conserved active site architecture and geometry, albeit
with residue differences (12,18,19). To investigate this,
we performed gel ﬁltration analysis of wild-type p56
with E. coli MUG and also a visual inhibition assay
with human SMUG. These experiments indicated that
p56 did not associate with either enzyme (Supplementary
File), which is in accord with reports of previous observa-
tions involving ugi (19).
Perusal of the structures of E. coli MUG and Xenopus
SMUG1 with superimposition onto our p56 complex to
model the possibility of p56 binding reveals that key struc-
ture and residue differences could explain the observed
lack of inhibition by p56. The critical points for compari-
son would be the HHV-1 UDG leucine 214 position and
its MUG or SMUG equivalents, as well as points along
the trajectory of contact of p56 (Figure 1).
With MUG, the structural reasons for lack of inter-
action with p56 are clearest. The MUG structure is gen-
erally more closed around the active site and the UDG
Leu214 equivalent position would be less accessible. At
the equivalent of phosphate position 1 (phosphate pos-
itions are described in Figure 3, and also in Supplementary
Table S1) the loop in UDG is a helix in MUG, and there
are no equivalences. With respect to p56, MUG residues
at the remaining equivalent DNA phosphate positions are
either obstructed, spatially removed or substituted and
oriented wrongly for interaction.
Table 2. A summary of data obtained for mutants of p56 and their interactions with HHV-1 UDG
PZA p56 protein variant Tagged HHV-1 UDG
afﬁnity co-puriﬁcation?
Dimer interface intact? Migration with
HHV-1 UDG on
gel ﬁltration?
Inhibition of U-DNA
degradation by HHV-1
UDG?
Wild-type Y Y Y Y
E37Q Y Y Y Not measured
E37D N Y Partial Partiala
Y40N N Impaired N (?) N
E37D/Y40N N Impaired N (?) N
Transit volumes in gel ﬁltration are indicative and supported by SDS–PAGE analysis of fractions across the peak areas (Supplementary File).
Degradation of a 100% uracil-DNA substrate can be graded as apparently complete or else inhibition may be seen as DNA being protected partially
or apparently completely.
aE37D can inhibit HHV-1 degradation of uracil-DNA, but not completely when compared with a sample in which wild-type p56 is present.
(?) The small shoulder on the gel ﬁltration trace (Supplementary File) close to the migration time for the HHV-1 UDG – p56 wild-type complex may
be an aggregation product of the p56 mutant in question. SDS–PAGE analysis of overloaded fractions from this part of the trace shows only a band
for p56, and not for UDG.
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In the case of SMUG, the most telling substitution is an
arginine in the place of the p56-targeted UDG leucine (or
phenylalanine in the B. subtilis structure). Arginine at this
point in Vaccinia UDG is known to be sufﬁcient to
prevent ugi from blocking UDG activity (11,21). If this
SMUG arginine alone would not be convincing enough a
reason for lack of inhibition by p56, then there is also the
fact that the SMUG DNA-binding cleft positions are not
entirely favourable for p56 binding. Although some points
along this path are well conserved, e.g. conserved serines
at phosphate positions 0 and +1 in both UDG and
SMUG, other key interactions are missing or else substi-
tutions would be unfavourable for interaction with p56.
Lastly, there is no equivalent to the minor groove loop
interactions; therefore, interaction is unlikely with p56.
These p56 incompatible features are also seen with
another UDG superfamily enzyme, TDG, which has
been included in the comparison in Figure 1.
Ugi features more extensive and tighter interactions
with HHV-1 UDG than we have observed with p56, and
furthermore it is able to displace p56 from UDG (27,28).
We ran a crude ugi displacement experiment of p56
co-puriﬁed as a complex with HHV-1 UDG. Following
overnight rotary incubation at 4C at microgram per milli-
litre concentration constituent of 2mg each of pure ugi
(StrepTag II tagged to allow it to be readily distinguished
from p56) and the pure HHV-1 UDG – PZA p56 complex,
we observed total displacement of p56 by ugi. We noted
that an estimated >80% of liberated p56 precipitated
during the course of this exchange. However, ordinarily
in ambient solution in the buffer that this experiment was
performed, p56 is stable up to tens of milligrams per milli-
litre concentration. This is suggestive of some degree of
structural destabilization during the course of displace-
ment of p56. This is potentially due to the hydrophobic
effects possible during exchange and would make this an
interesting system to investigate in greater depth.
DISCUSSION
We have observed inhibition of UDG by p56 to be func-
tionally analogous to UDG inhibition by ugi. The most
remarkable features of this convergent mechanism of
inhibition are that it is imparted by entirely unrelated pro-
teins and uses fundamentally different inhibitor protein
architecture in each case. Despite this, in their interactions
with UDG both inhibitors successfully mimic stereochem-
ical contacts consistent with B-DNA in the distorted form
imposed by UDG binding. In the case of ugi, this is from a
b-strand, but we observe that the p56 dimer recruits an
a-helix to this role.
Furthermore, this UDG-speciﬁc ‘DNA mimicry’ is sup-
ported in both inhibitors by the sequestration of a leucine
residue (phenylalanine, in the natural target of both
inhibitors, B. subtilis UDG) at the apex of a loop used
by UDG to insert into the DNA minor groove during
substrate recognition and catalysis. This contact in p56
may well represent the actual mode of inhibition of
UDG and at least appears necessary to provide stabil-
ity to what is otherwise a highly polar and largely
water-mediated set of contacts to the UDG DNA-
binding cleft. The extent of these polar contacts are also
relatively fewer, and in places more tenuous, in p56 when
compared with ugi (with reference to inhibitor complexes
involving HHV-1 UDG). The targeted UDG hydrophobic
residue is also, however, exquisitely speciﬁc to UDG func-
tionality. Both p56 and ugi are seen to use hydrophobic
pits to trap this apical loop leucine (phenylalanine in the
B. subtilis natural target of p56 and ugi); however, again
the altogether different structures confer different
features. The ﬂexibility of the UDG intercalation loop
gives rise to different leucine conformers in the p56 and
ugi complexes with HHV-1 UDG. This leucine conformer
is at least consistent across different UDGs in complex
with ugi (10,11) and therefore probably simply represents
the most favourable positioning, given the slight offset
between relative positions to UDG of the hydrophobic
traps of p56 and ugi.
In the case of ugi, which acts as a monomer when in-
hibiting UDG, the hydrophobic trap is relatively more
spatious, whereas in p56, it is narrow and comprised of
essential dimer interface residues. The structure of the p56
hydrophobic pit resembles a narrow open box, with its
diametric corners comprised of glutamate head groups
contacting tyrosyl hydroxyls. It is plausible that on its
way into this ‘box’, the UDG leucine is ‘forced’ past this
charged rim by superior forces that facilitate stable
docking of p56 to UDG. However, once inside it could
be trapped by a combination of the charged rim, above,
and the favourable environment, within. Finally, serine
residues ﬂanking the leucine on the UDG minor groove
DNA intercalation loop effectively seal it inside by
creating a ‘lid’ to the box via their interactions with the
charged corners of the rim. However, the relative import-
ance of these polar interactions could not be ascertained
by perusal of a 3 A˚ structure of a p56 E37Q mutant.
Pondering this ‘polar lid over a hydrophobic pocket’
was reminiscent of another analogy in ligand binding by
protein structure: the streptavidin tryptophan cluster, sup-
ported by polar loop closure over a bound biotin moiety
(43). If the hydrophobic traps of p56 and ugi, which we
ﬁnd analogous to such a tight-binding system, are the
main inhibitory interaction from these phage inhibitors
to UDG, then it would certainly explain their resistance
to dissociation even under harsh conditions.
Relative avidity for UDG of p56 and ugi
Comparatively, it has been demonstrated that ugi can
displace a p56 dimer from UDG (28). This might be due
in part to the relatively more extensive contacts of the ugi
inhibitory b-strand, compared with the p56 a-helix. If ugi
is able to initiate contact to UDG complexed with p56,
speculatively at the most polar end of the UDG DNA-
binding cleft where p56 serine 32 through p56 serine 34
reside, then it is possible that serial displacement of p56
contacts might occur. The ugi peripheral contacts to
UDG, which are not a feature of p56 interaction with
the HHV-1 enzyme, must also contribute to relative sta-
bility of a UDG – ugi complex. The strongest contact of
p56 to UDG is according to our data the trapped leucine;
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yet, if all other contacts are readily displaced by ugi, then
the ultimate displacement of p56 from UDG must accord-
ing to our data also be relatively assured. This would seem
to put blockade of the DNA-binding cleft in the frame
more as a UDG selectivity feature, rather than an inhibi-
tory feature under physiological conditions. When the
sequestration of HHV-1 UDG Leu214 is compromised
without apparent perturbation of the dimer interface, as
evidenced by our E37D p56 mutant, a large (but perhaps
not non-physiological in the throes of a phage infection)
molar excess over UDG (imperfect inhibition is discernable
at 100:1) is required to block HHV-1 UDG activity on
100% uracilated DNA. We would propose that the wild-
type protein in a phage infection would rapidly occupy
available UDG DNA-binding clefts, and we surmise that
the hydrophobic trap is the actual site of UDG inhibition
by p56. In our crude ‘p56 displacement from UDG by ugi’
experiment described in the ‘Results’ section, the 20% of
displaced p56 that remained in solution appeared to block
UDG activity as effectively as p56 prepared as an apo
protein. Therefore, any structural perturbation to p56
during forced removal from UDG by ugi must be recover-
able in a minority of events.
UDG sequestration and inhibition beyond p56 and ugi
From a naı¨ve perspective, all uracil-DNA phages must
have some means of neutralizing UDG activity. It is also
a fact that phages without genomic uracil-DNA content
encode p56-type proteins that directly inhibit UDG. With
the beneﬁt of our current observations, it is therefore
perhaps no longer as striking that there are few ORFs in
phage genomic accessions with anything more than limited
sequence homology to a UDG inhibitor of either known
type. This situation had been especially curious in the cases
of the uracil-DNA Yersinia phage fR1-37 and the canon-
ical DNA containing coliphage T5, which is reported to
encode a 10–15 kD protein that limits UDG activity
(6,23). The insights from our study would indicate that
bacteriophage proteins, and by extrapolation viral
proteins in general, can be unique in sequence and struc-
ture, yet analogous in function. This is doubtless owing to
the evolutionary pressures inherent in viral replication;
however, convergence would not appear to be rare in
protein–protein interactions in general (44). We might
now conjecture that the reported properties of the UDG
inhibiting protein induced by phage T5 appear curiously
analogous to our E37D mutant of p56. Could the T5
mechanism feature sufﬁciently effective speciﬁc targeting
and blockade of UDG without a requirement for tight
inhibition?
We should also bear in mind that the vista of
neutralization or modulation of UDG activity by viruses
also extends beyond the convergent mechanism described
in this report. Alternative types of UDG targeting are also
known from viruses of eukaryotes, which result in the
trafﬁcking and proteolytic degradation of UDG (45).
Modulation of UDG activity of any sort has implications
for viral genomic integrity in the informational sense. In
the case of HIV-1-infected cells, UDG is sequestered for
degradation by the viral protein Vpr, possibly because
signiﬁcant uracil content in HIV-1 DNA appears to be
an integral part of the early viral replication strategy
(46). Uracil in HIV-1 DNA, together with low-level
activity of the antiviral cytosine deaminase APOBEC-3G
modulated by the HIV-1 Vif protein, may also ensure a
potentially beneﬁcial mutagenic pool of viral progeny
(47–49).
UDG therefore constitutes a signiﬁcant barrier against
spontaneous cytosine to uracil conversion from being gen-
etically propagated, and its removal results in informa-
tional attrition. The fact that PBS1 DNA was found to
have a genomic GC content of 28% (5) appears to lend
some credence to the argument that its genomic GC
content is the result of a downward slide due to silencing
of uracil-DNA BER (2). However, bacteriophages T5, and
the f29 family, all target UDG activity but have higher
genomic GC contents of circa 40%. This difference might
be accounted for by the fact that PBS1 is also known to
subvert nucleotide biosynthesis pathways, actively
skewing the balance in favour of deoxyuridine nucleotide
formation (2). Such a downward slide in genomic GC
content could also be imagined to be the result of inhib-
ition of other repair systems, such as those targeting
8-oxoguanine. However, given the relative frequency of
oxidative damage, inhibition of such systems could
quickly become catastrophic for the virus through hyper-
mutation effects (47). Finally, other adaptation pressures
may act to lower GC content in phages (49). Nonetheless,
it would be interesting to assay for the viral inhibition of
BER systems targeting DNA lesions other than uracil.
In summary, we have observed remarkable mechanistic
convergence, and striking analogy in host enzyme-speciﬁc
targeting by two structurally disparate inhibitor proteins
encoded by unrelated bacteriophages. Other evidence
would also suggest that similar functionalities are at
large in the diverse universe of viral proteins. With the
beneﬁt of this knowledge, it will now be of some interest
to embark on detailed in silico studies backed up with
recombinant assays and structural biology. This could
lead to a more detailed description of diversity in UDG
inhibitors and could perhaps also reveal inhibitors of
other BER activities, via analysis of further putative
examples (6,23). The visual BER assay developed for the
work described provides a fast and effective readout for
this type of effect. Also, considering the wider roles now
assigned to UDG beyond DNA repair (48,50), such
discoveries would in turn enable studies to investigate
whether bacteriophages are the only viruses that directly
inhibit UDG by active site blockade. Enriching our know-
ledge of the sequence and structural signatures underlying
UDG inhibition might eventually reveal whether indeed
viruses are the only genomes to modulate UDG activity.
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